yes i take peptides · shopping companion

Survodutide

Category · For Weight LossStatus · RUOCitations · 60

The verdict

A dual GLP-1 and glucagon receptor agonist from Boehringer Ingelheim. Phase 2 hit 18.7% weight loss at 46 weeks — and a phase 2 MASH trial cleared liver fibrosis in nearly two-thirds of patients on the top dose.

By source — cost, legality, risk

Brand
Not available
None — Boehringer Ingelheim Phase 3 SYNCHRONIZE ongoing, no FDA approval yet
No FDA-approved survodutide exists yet.
Compounded 503A pharmacy
$400–$800/mo where available
Off-label compounding · not on FDA bulks list, pre-approval
Mid–high. Few compounders carry survodutide; selling under contested legal interpretations.
RUO research peptide
$150–$400/mo
Sold 'for research only'
Highest. Pre-approval molecule, no reference standards — identity verification very hard.
Gray-market raw
~$65/mo
Unregulated overseas import
Crypto/Wise pay; pre-approval molecule, identity-failures more common than the established GLP-1s.

Sources · top 5 of 60

01Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. The New England journal of medicine. 2024;391(4):311-319. PMID: 38847460.
02le Roux CW, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The lancet. Diabetes & endocrinology. 2024;12(3):162-173. PMID: 38330987.
03Blüher M, et al. Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024;67(3):470-482. PMID: 38095657.
04Kaya E, et al. Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction. Expert opinion on investigational drugs. 2024;33(12):1167-1176. PMID: 39663847.
05Lawitz EJ, et al. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. Journal of hepatology. 2024;81(5):837-846. PMID: 38857788.